398 related articles for article (PubMed ID: 26231052)
21. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
Colman S; Chapple C; Nitti V; Haag-Molkenteller C; Hastedt C; Massow U
Urology; 2008 Oct; 72(4):803-7. PubMed ID: 18722655
[TBL] [Abstract][Full Text] [Related]
22. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
23. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder.
Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N
Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200
[TBL] [Abstract][Full Text] [Related]
24. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
25. Symptom severity and patient perceptions in overactive bladder: how are they related?
Homma Y; Gotoh M
BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
[TBL] [Abstract][Full Text] [Related]
26. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.
Homma Y; Uemura S
BJU Int; 2004 May; 93(7):1009-13. PubMed ID: 15142153
[TBL] [Abstract][Full Text] [Related]
27. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
Coyne K; Revicki D; Hunt T; Corey R; Stewart W; Bentkover J; Kurth H; Abrams P
Qual Life Res; 2002 Sep; 11(6):563-74. PubMed ID: 12206577
[TBL] [Abstract][Full Text] [Related]
28. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
29. Reliability of the Polish version of the Overactive Bladder Symptom Score (OABSS) questionnaire : Correlation of the OABSS with urodynamic study and the UDI-6 and IIQ-7 questionnaires.
Wróbel A; Skorupska K; Rechberger E; Woźniak A; Miotla P; Kubik-Komar A; Skorupski P; Rechberger T
Int Urogynecol J; 2019 Dec; 30(12):2135-2139. PubMed ID: 31396639
[TBL] [Abstract][Full Text] [Related]
30. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
Sievert KD; Chapple C; Herschorn S; Joshi M; Zhou J; Nardo C; Nitti VW
Int J Clin Pract; 2014 Oct; 68(10):1246-56. PubMed ID: 24754838
[TBL] [Abstract][Full Text] [Related]
31. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
[TBL] [Abstract][Full Text] [Related]
32. Correlation between the Incontinence Severity Index (ISI) and the quality of life dimensions of the King's Health Questionnaire (KHQ) in German-speaking urinary incontinent women.
Brandt F; Solomayer EF; Sklavounos P
J Gynecol Obstet Hum Reprod; 2022 Feb; 51(2):102288. PubMed ID: 34902634
[TBL] [Abstract][Full Text] [Related]
33. The effect of EMG biofeedback assisted pelvic floor muscle therapy on symptoms of the overactive bladder syndrome in women: A randomized controlled trial.
Voorham JC; De Wachter S; Van den Bos TWL; Putter H; Lycklama À Nijeholt GA; Voorham-van der Zalm PJ
Neurourol Urodyn; 2017 Sep; 36(7):1796-1803. PubMed ID: 27869312
[TBL] [Abstract][Full Text] [Related]
34. Impact of self-perceived bothersomeness on health-related quality of life in women with overactive bladder symptoms.
Oh SJ; Ku JH
Urol Int; 2007; 78(1):63-9. PubMed ID: 17192735
[TBL] [Abstract][Full Text] [Related]
35. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
[TBL] [Abstract][Full Text] [Related]
36. Is there any association between urodynamic variables and severity of overactive bladder in women with idiopathic detrusor overactivity?
Giarenis I; Zacchè M; Robinson D; Cardozo L
Neurourol Urodyn; 2017 Mar; 36(3):780-783. PubMed ID: 27092808
[TBL] [Abstract][Full Text] [Related]
37. Impact of stress urinary incontinence and overactive bladder on micturition patterns and health-related quality of life.
Oh SJ; Ku JH
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jan; 18(1):65-71. PubMed ID: 16575487
[TBL] [Abstract][Full Text] [Related]
38. Black box in overactive bladder: Central sensitization and its relationship with urinary symptom severity and quality of life.
Celenay ST; Altay H; Bulbul SB; Oskay K
Neurourol Urodyn; 2024 Mar; 43(3):620-627. PubMed ID: 38221860
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in the setting of a randomized control trial on the efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome.
Ramírez-García I; Kauffmann S; Blanco-Ratto L; Carralero-Martínez A; Sánchez E
Neurourol Urodyn; 2021 Jan; 40(1):295-302. PubMed ID: 33118624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
